Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 774 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 504 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 639 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 756 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 404 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 317 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 376 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 458 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 4,775 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
ABCELLERA BIOLOGICS | 3,679 | -0,38 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
ANAVEX LIFE SCIENCES | 7,660 | -0,80 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial | New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision... ► Artikel lesen | |
VERACYTE | 26,000 | -3,70 % | S&P Dow Jones Indices: Veracyte Set to Join S&P SmallCap 600 | NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the... ► Artikel lesen | |
ASCLETIS PHARMA | 1,240 | -3,12 % | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - VOLUNTARY LOCK-UP UNDERTAKING MADE BY CONTROLLING SHAREHOLDERS | ||
BIOMEA FUSION | 1,960 | +1,82 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
JASPER THERAPEUTICS | 2,380 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody... ► Artikel lesen | |
ABSCI | 2,620 | 0,00 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
LANTERN PHARMA | 3,810 | 0,00 % | RedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 | ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive... ► Artikel lesen | |
Y-MABS THERAPEUTICS | 8,610 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
BIONTECH | 83,20 | -0,06 % | BioNTech Aktie: Ist das der Startschuss für den Krebs-Killer aus Mainz? | © Foto: Foto von FRANK MERIÑO auf PexelsDas Warten hat endlich ein Ende. BioNTech schreibt mit seinem Krebsmedikament BNT323 Medizingeschichte.Nach jahrelanger Forschung meldet das Mainzer Unternehmen... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
APOGEE THERAPEUTICS | 36,860 | -0,05 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
QIAGEN | 38,395 | -1,26 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen |